unprofitable

CRISPR Therapeutics stock declined 9% following a $585.2M convertible notes offering. The gene-editing company boasts FDA-approved Casgevy therapy and $1.8B in reserves but faces steep losses.

SoundHound AI stock down 66% despite nearly doubling revenue to $169M. Company guides 33-50% 2026 growth but remains unprofitable with contingent liabilities.

TMC receives positive NOAA feedback for deep-seabed mining application but remains unprofitable with substantial regulatory and operational risks. Suitable only for aggressive investors.

Sweetgreen stock has collapsed 89% from its $52 IPO price to $5.52, plagued by near-zero growth and $134M annual losses. Reaching $10 requires a turnaround analysts don't foresee.

Wayfair shows 6.9% revenue growth and narrowing losses, attracting bullish analyst outlooks with 42-82% upside potential. Strategic expansions include membership programs and physical retail, though profitability remains uncertain.